Liposomal Irinotecan: A Review in Metastatic Pancreatic Adenocarcinoma
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Liposomal Irinotecan: A Review in Metastatic Pancreatic Adenocarcinoma
Authors
Keywords
-
Journal
DRUGS
Volume 80, Issue 10, Pages 1007-1018
Publisher
Springer Science and Business Media LLC
Online
2020-06-17
DOI
10.1007/s40265-020-01336-6
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Observational retrospective evaluation of treatment with liposomal irinotecan plus fluorouracil/leucovorin for metastatic pancreatic cancer patients: An Italian large real-world analysis.
- (2020) Antonio Pellino et al. JOURNAL OF CLINICAL ONCOLOGY
- Impact of dose reductions on clinical outcomes among patients (pts) with metastatic pancreatic cancer (mPC) treated with liposomal irinotecan (nal-IRI) in oncology clinics in the United States.
- (2020) Paul Cockrum et al. JOURNAL OF CLINICAL ONCOLOGY
- Real-World Dosing Patterns and Outcomes of Patients With Metastatic Pancreatic Cancer Treated With a Liposomal Irinotecan Regimen in the United States
- (2020) Afsaneh Barzi et al. PANCREAS
- Impact of New Chemotherapy Regimens on the Treatment Landscape and Survival of Locally Advanced and Metastatic Pancreatic Cancer Patients
- (2020) Markus Kieler et al. Journal of Clinical Medicine
- The Impact of Liposomal Irinotecan on the Treatment of Advanced Pancreatic Adenocarcinoma: Real-World Experience in a Taiwanese Cohort
- (2020) Yung-Yeh Su et al. Scientific Reports
- Spotlight on liposomal irinotecan for metastatic pancreatic cancer: patient selection and perspectives
- (2019) Wonhee Woo et al. OncoTargets and Therapy
- Liposomal irinotecan and 5-fluorouracil/leucovorin in older patients with metastatic pancreatic cancer – A subgroup analysis of the pivotal NAPOLI-1 trial
- (2019) Teresa Macarulla et al. Journal of Geriatric Oncology
- NAPOLI-1 phase 3 study of liposomal irinotecan in metastatic pancreatic cancer: Final overall survival analysis and characteristics of long-term survivors
- (2019) Andrea Wang-Gillam et al. EUROPEAN JOURNAL OF CANCER
- P-271Efficacy and tolerability of the combination of Liposomal irinotecan and 5-fluorouracil/leucovorin in advanced pancreatic cancers: post-approval clinic experience
- (2019) R Paluri et al. ANNALS OF ONCOLOGY
- PCN16 IMPACT OF TREATMENT SEQUENCE ON OVERALL SURVIVAL IN METASTATIC PANCREATIC CANCER PATIENTS TREATED WITH LIPOSOMAL IRINOTECAN IN THE REAL-WORLD SETTING
- (2019) G.P. Kim et al. VALUE IN HEALTH
- Nomogram for Predicting Survival in Patients Treated with Liposomal Irinotecan Plus Fluorouracil and Leucovorin in Metastatic Pancreatic Cancer
- (2019) Chen et al. Cancers
- Comparison of conventional versus liposomal irinotecan in combination with fluorouracil for advanced pancreatic cancer: a single-institution experience
- (2019) Justin C. Tossey et al. MEDICAL ONCOLOGY
- Pancreatic ductal adenocarcinoma: biological hallmarks, current status, and future perspectives of combined modality treatment approaches
- (2019) Michael Orth et al. Radiation Oncology
- 691PIntegrated population pharmacokinetic modelling of liposomal irinotecan in patients with various tumour types, including untreated metastatic pancreatic cancer (mPC)
- (2019) T Macarulla et al. ANNALS OF ONCOLOGY
- Liposomal irinotecan in metastatic pancreatic adenocarcinoma in Asian patients: Subgroup analysis of the NAPOLI‐1 study
- (2019) Yung‐Jue Bang et al. CANCER SCIENCE
- Liposomal Irinotecan + 5-FU/LV in Metastatic Pancreatic Cancer
- (2019) Teresa Macarulla Mercadé et al. PANCREAS
- Nanoliposomal irinotecan with fluorouracil for the treatment of advanced pancreatic cancer, a single institution experience
- (2018) Danielle C. Glassman et al. BMC CANCER
- Individualization of Irinotecan Treatment: A Review of Pharmacokinetics, Pharmacodynamics, and Pharmacogenetics
- (2018) Femke M. de Man et al. CLINICAL PHARMACOKINETICS
- Towards an optimal treatment algorithm for metastatic pancreatic ductal adenocarcinoma (PDA)
- (2018) M. Uccello et al. Current Oncology
- Metastatic Pancreatic Cancer: ASCO Clinical Practice Guideline Update
- (2018) Davendra P.S. Sohal et al. JOURNAL OF CLINICAL ONCOLOGY
- Quality of life in metastatic pancreatic cancer patients receiving liposomal irinotecan plus 5-fluorouracil and leucovorin
- (2018) Richard A. Hubner et al. EUROPEAN JOURNAL OF CANCER
- Survival with nal-IRI (liposomal irinotecan) plus 5-fluorouracil and leucovorin versus 5-fluorouracil and leucovorin in per-protocol and non-per-protocol populations of NAPOLI-1: Expanded analysis of a global phase 3 trial
- (2018) Li-Tzong Chen et al. EUROPEAN JOURNAL OF CANCER
- Second line treatment options for pancreatic cancer
- (2017) Frank C. Passero et al. EXPERT OPINION ON PHARMACOTHERAPY
- Pancreatic Adenocarcinoma, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology
- (2017) Margaret A. Tempero et al. Journal of the National Comprehensive Cancer Network
- Liposomal irinotecan in gemcitabine-refractory metastatic pancreatic cancer: efficacy, safety and place in therapy
- (2017) Emma Kipps et al. Therapeutic Advances in Medical Oncology
- Nanoliposomal irinotecan plus fluorouracil and folinic acid: a new treatment option in metastatic pancreatic cancer
- (2016) Sana Saif Ur Rehman et al. Expert Review of Anticancer Therapy
- Pancreatic cancer: yesterday, today and tomorrow
- (2016) Daniel Ansari et al. Future Oncology
- Nanomedicine developments in the treatment of metastatic pancreatic cancer: focus on nanoliposomal irinotecan
- (2016) Andrew Ko International Journal of Nanomedicine
- Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial
- (2016) Andrea Wang-Gillam et al. LANCET
- Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- (2015) M. Ducreux et al. ANNALS OF ONCOLOGY
- A multinational phase 2 study of nanoliposomal irinotecan sucrosofate (PEP02, MM-398) for patients with gemcitabine-refractory metastatic pancreatic cancer
- (2013) A H Ko et al. BRITISH JOURNAL OF CANCER
- Pancreatic cancer: surgical management and outcomes after 6 years of follow-up
- (2012) Antony G Speer et al. MEDICAL JOURNAL OF AUSTRALIA
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started